Group items matching

in title, tags, annotations or url

The biennial prize provides a $100,000 honorarium, national and international recognition, and support to an international leader in the clinical sciences of cardiovascular medicine, cardiothoracic surgery, or the basic sciences of molecular or cellular cardiology.

This initiative of the Burroughs Wellcome Fund is focused on providing support for academic researchers developing new methodologies or innovative approaches in regulatory science that will ultimately inform the regulatory decisions FDA and others make.  This would necessarily draw upon the talents of individuals trained in mathematics, computer science, applied physics, medicine, engineering, toxicology, epidemiology, biostatistics, and systems pharmacology, to name a few.

The Communications, Circuits, and Sensing-Systems (CCSS) program is intended to spur visionary systems-oriented activities in collaborative, multidisciplinary, and integrative research. CCSS supports systems research in hardware, signal processing techniques, and architectures to enable the next generation of cyber-physical systems (CPS) that leverage computation, communication, and algorithms integrated with physical domains. CCSS offers new challenges at all levels of systems integration to address future societal needs. CCSS supports innovative research and integrated educational activities in micro- and nano-systems, communications systems, and cyber-physical systems. The goal is to design, develop, and implement new complex and hybrid systems at all scales, including nano, micro, and macro, that lead to innovative engineering principles and solutions for a variety of application domains including, but not limited to, healthcare, medicine, environmental monitoring, communications, disaster mitigation, homeland security, transportation, manufacturing, energy, and smart buildings. CCSS also supports integration technologies at both intra-and inter-chip levels, new and advanced radio frequency (RF), millimeter wave and optical wireless and hybrid communications systems architectures, and sensing and imaging at terahertz (THz) frequencies.

This Funding Opportunity Announcement (FOA) issued by the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM), builds upon the National Antimicrobial Resistance Monitoring System (NARMS) which was initiated in 1996 as one of the key activities in a national action plan to combat antibiotic resistance threats. The purpose of this FOA is to protect and promote public health by enhancing, strengthening and sustaining antibiotic resistance surveillance in retail food specimens within the NARMS program. The NARMS cooperative agreements will improve the detection of antibiotic resistance among enteric bacteria in food commodities, as well as potentially develop new sites as part of the program. Measurable outcomes of the program will be in alignment with the NARMS Objectives.

Cell-based therapies, especially immune cells, have the potential to revolutionize human healthcare in various different contexts, including cancer and personalized medicine. For example, CAR (Chimeric antigen receptor) T-cell therapy for cancer requires modification, in vitro culture and expansion of human T-cells.   Manufacturing of therapeutic cells as the end product presents major engineering challenges.  New therapies and cell-based products depend critically on the development of robust, reliable and reproducible biomanufacturing technologies.

The American Society for Radiation Oncology is accepting applications for its 2019 Minority Summer Fellowship Award. The annual program is designed to introduce medical students from backgrounds that are underrepresented in medicine to the discipline of radiation oncology early in their medical education. Although medical students in all years are encouraged to apply, preference will be given to first- and second-year students. In an effort to promote radiation oncology as a career choice, the fellowship will expose medical students to clinical, basic, and translational research questions in radiation oncology. The fellowship provides each student with a $4,500 package that includes a $3,500 stipend for the eight-week training program (exceptions can be made for a longer program but will need to be approved by ASTRO's Committee on Health Equity, Diversity and Inclusion, or "CHEDI") and $1,000 toward the cost of travel to the organization's 2019 annual meeting. To be eligible, applicants must be enrolled in a United States medical school and be able to identify a mentor with a successful record of research productivity. The mentor should be an ASTRO member. In addition, research must be undertaken at a North American institution during the summer of 2019.

The SPURS experience is intended to provide meaningful training in biomedical research and enhance students' ability to achieve a career in biomedical research and/or medicine by pursuing an advanced degree. Each student is matched with a mentor on the Columbia faculty who specializes in his or her field of interest. In addition to specific training in their research area of interest, students receive in-depth training in biomedical research methodology,  including the design and evaluation of experiments; critical reading of the scientific literature; presentation of scientific results at laboratory meetings; preparation of posters, abstracts, and manuscripts; and career counseling.

This program supports highly creative individuals in NHGRI priority research areas, such as the development of resources, approaches, or technologies that will accelerate genomic research on the structure of genomes, the biology of genomes, or the biology of disease; that will advance the science of genomic medicine; that will incorporate genomics to improve the effectiveness of healthcare; or that will advance genomic technology development, computational genomics, or research on the ethical, legal, and societal implications of genomics and genetics research.  This program supports the development of approaches that can be used broadly.  A hallmark of genomic research is comprehensiveness across the genome, such as all genes, variants, or regulatory elements, rather than specific sets.  The focus should be on developing approaches that can be applied generally, although an approach may be tested with specific genes, genomic elements, variants, cell types, diseases, traits, or model organisms.  Studies that focus on one or a few specific genes should be paradigm-setting and yield findings relevant at the genomic level.  The application should explain how broadly useful the approaches will be.

The Beckman Center for the History of Chemistry at the Chemical Heritage Foundation, an independent research library in Philadelphia, is inviting applications for short- or long-term fellowships in the history of science, technology, medicine, and industry. The research collections at CHF range chronologically from the fifteenth century to the present and include six thousand rare books, significant archival holdings, thousands of images, and a large artifact and fine arts collection, supported by over one hundred thousand reference volumes and journals. Within the collections there are many areas of special strength, including alchemy, mining & metallurgy, dyeing and bleaching, balneology, gunpowder and pyrotechnics, gas-lighting, books of secrets, inorganic and organic chemistry, biochemistry, food chemistry, and pharmaceuticals.

þffThe National Institute of Dental and Craniofacial Research (NIDCR) is firmly committed to facilitating clinical translation of the most promising scientific and technological advances in tissue engineering and regenerative medicine (TE/RM) to safely and efficaciously regenerate and reconstruct dental, oral and craniofacial (DOC) tissues. Toward achieving this goal, NIDCR had established a multidisciplinary DOC Tissue Regeneration Consortium (DOCTRC) that consists of three Stages. For Stage 1, one year of support was provided under RFA-DE-15-005 through the R34 Planning Grant funding mechanism to develop an overall vision, roadmap, organizational structure, operational procedures and detailed plans for establishing centralized Resource Centers (RCs).

The Air Force Office of Scientific Research (AFOSR) seeks unclassified proposals for broad-based research and development aimed at using lasers and other light source technology to develop applications in medicine, photobiology, surgery, and closely related materials sciences, with applications to combat casualty care and other military medical problems. This announcement is primarily directed toward university-based medical institutions; however, all qualified and responsible prime applicants located in the United States are eligible to submit proposals. The highest priority will be extended to proposals up to three (3) years duration to be conducted by teams of physicians, biomedical scientists, physical scientists, and engineers. The efforts proposed may be basic or applied research, and must have direct relevance to combat casualty care or other military medical priorities. Applicants must demonstrate substantial experience working to further military medical priorities, including transitioning research into clinical practice and working products. Substantial experience collaborating with military medical centers is also a requirement to establish relevance to combat casualty care or other military medical priorities, and facilitate the transition of research results to meet military needs. Applicants are encouraged to apply as early as practicable. Proposals may be reviewed and selected as received. Awards may take the form of grants or contracts

NBF will award grants for investigator-initiated original research focused on any aspect of blood banking, transfusion medicine, cellular therapies, or patient blood management. Grants will support one- or two-year research projects with a maximum award of $75,000.

The Air Force Office of Scientific Research (AFOSR) seeks unclassified proposals for research and development aimed at using lasers and other light source technology to develop applications in medicine, photobiology, surgery, and closely related materials sciences, with applications to combat casualty care and other military medical problems. This announcement is for a small number of individual awards. It is complementary to ongoing and future planed broad based awards, primarily directed toward university-based medical institutions, conducted by teams of physicians, biomedical scientists, physical scientists, and engineers. The efforts proposed may be basic or applied research, and must have direct relevance to combat casualty care or other military medical priorities. They must offer unique capabilities, not substantially funded by other DOD or other agency programs. Applicants must demonstrate substantial experience working to further military medical priorities, including transitioning research into clinical practice and working products. Substantial experience collaborating with military medical centers is also a requirement to establish relevance to combat casualty care or other military medical priorities, and facilitate the transition of research results to meet military needs.

The Centers of Excellence in Genomic Science (CEGS) program establishes academic Centers for advanced genome research. Each CEGS award supports a multi-investigator, interdisciplinary team to develop transformative genomic approaches to address a biomedical problem. A CEGS project will address a critical issue in genomic science or genomic medicine, proposing a highly innovative solution that would be a major advance. The research will entail substantial risk, balanced by outstanding scientific and management plans and very high potential payoff. A CEGS will focus on the development of novel technological or computational methods for the production or analysis of comprehensive data sets, on a genome-scale biomedical problem, or on other ways to develop and use genomic approaches for understanding biological systems or furthering the application of genomic knowledge, data, and methods towards clinical applications. Each CEGS will nurture genomic science at its institution by facilitating the interaction of investigators from several disciplines. By training new and experienced investigators it will expand the pool of genomics scientists and engineers.

The DOE Isotope Program (IP), managed by SC Nuclear Physics (NP), hereby announces its interest in receiving applications for Research and Development (R&D) on novel methods to produce or improve production radioactive or enriched stable isotopes needed for a wide variety of research and applications. This announcement is administered under the NP Isotope Development & Production for Research and Applications (IDPRA) Sub-Program. The proposed R&D should generate data relevant to isotope production or lead to new and innovative technologies, or improvements to existing technologies to foster enhanced production of isotopes. Successful proposals will clearly describe how the outcome of the proposed work would support and enhance the production of isotopes used for research and applications in medicine, homeland security, the physical sciences, biological and geological sciences, energy, industry, etc. Applications incorporating effective ways to train personnel with essential knowledge and skills related to the production, processing, purification, and distribution of enriched stable and radioactive isotopes are strongly encouraged. A companion Program Announcement to DOE National Laboratories (LAB-1896) will be posted on the SC Grants and Contracts web site at: https://science.energy.gov/grants. Applications submitted to this FOA will be evaluated by peer review competitively with those submitted to the Laboratory companion announcement.

The Division of Mathematical Sciences (DMS) in the Directorate for Mathematical and Physical Sciences (MPS) at the National Science Foundation (NSF) and the National Library of Medicine (NLM)at the National Institutes of Health (NIH)plan to support the development of innovative and transformative mathematical and statistical approaches to address important data-driven biomedical and health challenges. The rationale for this interagency collaboration is that significant advances may be expected as the result of continued NSF investments in foundational research in mathematics and statistics as well as inter- and multi-disciplinary research and training at the intersection of the quantitative/computational sciences and domain sciences, while NIH benefits from the enhancement of biomedical data science with new approaches that strengthen the reproducibility of biomedical research and support open science.

The goal of the interagency Smart and Connected Health (SCH): Connecting Data, People and Systems program is to accelerate the development and integration of innovative computer and information science and engineering approaches to support the transformation of health and medicine. Approaches that partner technology-based solutions with biomedical and biobehavioral research are supported by multiple agencies of the federal government including the National Science Foundation (NSF) and the National Institutes of Health (NIH). The purpose of this program is to develop next-generation multidisciplinary science that encourages existing and new research communities to focus on breakthrough ideas in a variety of areas of value to health, such as networking, pervasive computing, advanced analytics, sensor integration, privacy and security, modeling of socio-behavioral and cognitive processes and system and process modeling. Effective solutions must satisfy a multitude of constraints arising from clinical/medical needs, barriers to change, heterogeneity of data, semantic mismatch and limitations of current cyberphysical systems and an aging population. Such solutions demand multidisciplinary teams ready to address issues ranging from fundamental science and engineering to medical and public health practice.

The purpose of this funding opportunity announcement (FOA) is to promote the discovery of novel small molecules that may enhance the ability of the immune system to selectively recognize and attack cancer cells. These small molecules could be further developed into stand-alone immunotherapeutics or synergistic partners for existing therapies, or as chemical probes for the discovery and validation of novel targets involved in anti-tumor immunity. Investigators from multiple scientific disciplines (immuno-oncology, tumor biology, screening technology, medicinal chemistry, and pharmacology) are encouraged to establish collaborative teams to discover and develop novel small molecule immunomodulators for cancer therapy. This FOA encourages the design of research projects that utilize the following phases of discovery research: 1) assay development specifically designed for immuno-oncology targets with the intent to screen for novel small molecule compounds that show potential as either probes or drugs, or as pre-therapeutic leads; 2) screen implementation for immunomodulatory targets to identify initial screening hits (from high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches); 3) hit validation through secondary orthogonal and counter screening assays, and hit prioritization; and 4) hit-to-lead optimization.

The purpose of this funding opportunity announcement (FOA) is to promote the discovery of novel small molecules that may enhance the ability of the immune system to selectively recognize and attack cancer cells. These small molecules could be further developed into stand-alone immunotherapeutics or synergistic partners for existing therapies, or as chemical probes for the discovery and validation of novel targets involved in anti-tumor immunity. Investigators from multiple scientific disciplines (immuno-oncology, tumor biology, screening technology, medicinal chemistry, and pharmacology) are encouraged to establish collaborative teams to discover and develop novel small molecule immunomodulators for cancer therapy. This FOA encourages the design of research projects that utilize the following phases of discovery research: 1) assay development specifically designed for immuno-oncology targets with the intent to screen for novel small molecule compounds that show potential as either probes or drugs, or as pre-therapeutic leads; 2) screen implementation for immunomodulatory targets to identify initial screening hits (from high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches); 3) hit validation through secondary orthogonal and counter screening assays, and hit prioritization; and 4) hit-to-lead optimization.

The mission of BTO is to foster, demonstrate, and transition breakthrough fundamental research, discoveries, and applications that integrate biology, engineering, computer science, mathematics, and the physical sciences. BTO's investment portfolio goes far beyond life sciences applications in medicine to include areas of research such as human-machine interfaces, microbes as production platforms, and deep exploration of the impact of evolving ecologies and environments on U.S. readiness and capabilities. BTO's programs operate across a wide range of scales, from individual cells to the warfighter to global ecosystems. BTO responds to the urgent and long-term needs of the Department of Defense (DoD) and addresses national security priorities.